Cargando…

Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis

Antimitochondrial antibodies (AMA) are the serum hallmark of primary biliary cirrhosis (PBC). However, AMA-positivity can be found in non-PBC sera when lower dilutions are used, thus raising issues about the specificity and sensitivity of the test. AMA reacts primarily with the lipoylated domains of...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyakawa, Hiroshi, Tanaka, Atsushi, Selmi, Carlo, Hosoya, Naomi, Mataki, Norikazu, Kikuchi, Kentaro, Kato, Takashi, Arai, Junya, Goto, Toshihiro, Gershwin, M. Eric
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270775/
https://www.ncbi.nlm.nih.gov/pubmed/17162370
http://dx.doi.org/10.1080/17402520600668706
_version_ 1782151759828877312
author Miyakawa, Hiroshi
Tanaka, Atsushi
Selmi, Carlo
Hosoya, Naomi
Mataki, Norikazu
Kikuchi, Kentaro
Kato, Takashi
Arai, Junya
Goto, Toshihiro
Gershwin, M. Eric
author_facet Miyakawa, Hiroshi
Tanaka, Atsushi
Selmi, Carlo
Hosoya, Naomi
Mataki, Norikazu
Kikuchi, Kentaro
Kato, Takashi
Arai, Junya
Goto, Toshihiro
Gershwin, M. Eric
author_sort Miyakawa, Hiroshi
collection PubMed
description Antimitochondrial antibodies (AMA) are the serum hallmark of primary biliary cirrhosis (PBC). However, AMA-positivity can be found in non-PBC sera when lower dilutions are used, thus raising issues about the specificity and sensitivity of the test. AMA reacts primarily with the lipoylated domains of pyruvate dehydrogenase-E2 (PDC-E2) which is highly conserved across species, including bacteria. We studied 77 serum samples, including 24 from patients with anti-PDC-E2-positive PBC and 53 controls (16 with autoimmune hepatitis (AIH), 10 with primary sclerosing cholangitis (PSC), and 27 healthy individuals) for their reactivities at serial dilutions (1:10, 1:20 and 1:40) against Escherichia coli DH5 alpha lysate overexpressing human PDC-E2 using immunoblotting (IB). A murine anti-human PDC-E2 monoclonal antibody (mAB) was used as control. We further studied positive sera using adsorption with a synthetic E. coli peptide sharing similarity with human PDC-E2. Finally, we verified whether a unique buffer for E. coli preparation could reduce non-specific serum reactivity. Results demonstrated that 100% of anti-PDC-E2-positive PBC and up to 38% of control sera at 1:10 dilution recognized E. coli PDC-E2 at IB while dilution tests indicated that the overall potency of PBC reactivity was 100-fold higher compared to controls. In fact, a subgroup (20-38%) of non-PBC sera were positive at low titers but lost the reactivity when absorbed with the synthetic E. coli peptide. Finally, our unique buffer reduced the reactivity of non-PBC sera as measured by ELISA. In conclusion, we demonstrated that weak cross-reactivity with E. coli PDC-E2 occurs in non-PBC sera at lower dilutions and that such reactivity is not due to AMA-positivity. The use of a specific buffer might avoid the risk of false positive AMA determinations when E. coli-expressed recombinant antigens are used.
format Text
id pubmed-2270775
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-22707752008-03-31 Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis Miyakawa, Hiroshi Tanaka, Atsushi Selmi, Carlo Hosoya, Naomi Mataki, Norikazu Kikuchi, Kentaro Kato, Takashi Arai, Junya Goto, Toshihiro Gershwin, M. Eric Clin Dev Immunol Research Article Antimitochondrial antibodies (AMA) are the serum hallmark of primary biliary cirrhosis (PBC). However, AMA-positivity can be found in non-PBC sera when lower dilutions are used, thus raising issues about the specificity and sensitivity of the test. AMA reacts primarily with the lipoylated domains of pyruvate dehydrogenase-E2 (PDC-E2) which is highly conserved across species, including bacteria. We studied 77 serum samples, including 24 from patients with anti-PDC-E2-positive PBC and 53 controls (16 with autoimmune hepatitis (AIH), 10 with primary sclerosing cholangitis (PSC), and 27 healthy individuals) for their reactivities at serial dilutions (1:10, 1:20 and 1:40) against Escherichia coli DH5 alpha lysate overexpressing human PDC-E2 using immunoblotting (IB). A murine anti-human PDC-E2 monoclonal antibody (mAB) was used as control. We further studied positive sera using adsorption with a synthetic E. coli peptide sharing similarity with human PDC-E2. Finally, we verified whether a unique buffer for E. coli preparation could reduce non-specific serum reactivity. Results demonstrated that 100% of anti-PDC-E2-positive PBC and up to 38% of control sera at 1:10 dilution recognized E. coli PDC-E2 at IB while dilution tests indicated that the overall potency of PBC reactivity was 100-fold higher compared to controls. In fact, a subgroup (20-38%) of non-PBC sera were positive at low titers but lost the reactivity when absorbed with the synthetic E. coli peptide. Finally, our unique buffer reduced the reactivity of non-PBC sera as measured by ELISA. In conclusion, we demonstrated that weak cross-reactivity with E. coli PDC-E2 occurs in non-PBC sera at lower dilutions and that such reactivity is not due to AMA-positivity. The use of a specific buffer might avoid the risk of false positive AMA determinations when E. coli-expressed recombinant antigens are used. Hindawi Publishing Corporation 2006 /pmc/articles/PMC2270775/ /pubmed/17162370 http://dx.doi.org/10.1080/17402520600668706 Text en Copyright © 2006 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Miyakawa, Hiroshi
Tanaka, Atsushi
Selmi, Carlo
Hosoya, Naomi
Mataki, Norikazu
Kikuchi, Kentaro
Kato, Takashi
Arai, Junya
Goto, Toshihiro
Gershwin, M. Eric
Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis
title Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis
title_full Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis
title_fullStr Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis
title_full_unstemmed Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis
title_short Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis
title_sort serum reactivity against bacterial pyruvate dehydrogenase: increasing the specificity of anti-mitochondrial antibodies for the diagnosis of primary biliary cirrhosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270775/
https://www.ncbi.nlm.nih.gov/pubmed/17162370
http://dx.doi.org/10.1080/17402520600668706
work_keys_str_mv AT miyakawahiroshi serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT tanakaatsushi serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT selmicarlo serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT hosoyanaomi serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT matakinorikazu serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT kikuchikentaro serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT katotakashi serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT araijunya serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT gototoshihiro serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis
AT gershwinmeric serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis